Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
AACR 2022
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
AACR 2022
In an interview from #ASH25, @Dr_AmerZeidan (@Yale) shares insights from a secondary analysis of the IMerge trial, which identified a correlation between treatment-emergent cytopenias and clinical response in patients with LR-MDS receiving imetelstat.
Watch here: 👉…
Want to hear results from the Phase III BRUIN-CLL-314 study comparing pirtobrutinib to ibrutinib in treatment-naïve and R/R CLL?
Watch our interview with Jennifer Woyach (@OSUCCC_James) from #ASH25 here:
🎥
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate…
Pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL: findings from BRUIN-CLL-314
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, shares results from the Phase III BRUIN-CLL-314 study ...
ow.ly
Couldn't make it to #ASH25?🩸
Lucky for you, we've got hundreds of expert interviews from the event on https://ow.ly/NOwN50XGJ0i, so that you can catch up on the latest updates and advances quickly and easily! 🎥😃
Click here to explore our exclusive coverage:
👉…
When comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL, which technique is superior?🤔🩸
@NicholasShortMD of @MDAndersonNews discusses this in an interview from #ASH25! 🎥
Click here to watch: 👉
#ALLsm #Leusm #Leukemia #MRD #HemOnc
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of a co...
ow.ly
The initial results of the MagnetisMM-30 trial combining elranatamab + iberdomide in patients with R/R #myeloma were presented at #ASH25 by @suvannasankha of @IUCancerCenter.
Watch our insightful video interview with Dr Suvannasankha to find out more:
👉 …
Initial results from MagnetisMM-30: elranatamab plus iberdomide in RRMM
Attaya Suvannasankha, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, discusse...
ow.ly
